LONDON (Thomson Financial) - Phytopharm PLC has been given the go ahead to start a second early stage trial of Myogane, an experimental treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, the most prevalent form of motor neurone disease. British regulators have given the green light for a phase Ib trial, in healthy volunteers, to assess the safety, tolerability and chemical profile of the drug.
